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Although anti-human immunodeficiency virus type 1 (HIV-1) therapies have becomemore sophisticated andmore effective,
drug resistance continues to be a major problem. Zidovudine (azidothymidine; AZT) was the first nucleoside reverse transcrip-
tase (RT) inhibitor (NRTI) approved for the treatment of HIV-1 infections and is still being used, particularly in the developing
world. This drug targets the conversion of single-stranded RNA to double-stranded DNA by HIV-1 RT. However, resistance to
the drug quickly appeared both in viruses replicating in cells in culture and in patients undergoing AZTmonotherapy. The pri-
mary resistance pathway selects for mutations of T215 that change the threonine to either a tyrosine or a phenylalanine (T215Y/
F); this resistance pathway involves an ATP-dependent excisionmechanism. The pseudo-sugar ring of AZT lacks a 3= OH; RT
incorporates AZTmonophosphate (AZTMP), which blocks the end of the viral DNA primer. AZT-resistant forms of HIV-1 RT
use ATP in an excision reaction to unblock the 3= end of the primer strand, allowing its extension by RT. The T215Y AZT resis-
tance mutation is often accompanied by two other mutations, M41L and L210W. In this study, the roles of these mutations, in
combination with T215Y, were examined to determine whether they affect polymerization and excision by HIV-1 RT. TheM41L
mutation appears to help restore the DNA polymerization activity of RT containing the T215Ymutation and also enhances
AZTMP excision. The L210Wmutation plays a similar role, but it enhances excision by RTs that carry the T215Ymutation when
ATP is present at a low concentration.
Generally speaking, most mutations in HIV-1 reverse trans-criptase (RT) have a negative impact on the enzyme; the pri-
mary mutations that cause zidovudine (AZT) resistance are not
exceptions. In some cases, secondary mutations are selected in
viruses that are replicating in patients because these mutations
help to compensate for the deleterious effects of primary resis-
tance mutations. In other cases, the most important effect of a
secondary mutation is to cause a further decrease in the suscepti-
bility of the virus to the inhibitor. In this report, we have analyzed
the effects of the secondary mutations M41L and L210W, in the
presence of the primary mutation T215Y, on both ATP-depen-
dent AZTMP excision and polymerase activities of HIV-1 RT to
determine whether these secondary mutations enhance the exci-
sion of AZTMP by RT and/or act as compensatory mutations that
partially restore the reduced polymerase activity of the T215Y
mutant.
During the replication of HIV-1, the single-stranded RNA ge-
nome is converted into double-stranded DNA by HIV-1 RT. This
conversion requires both enzymatic activities of RT: a DNA poly-
merase that can copy either an RNA or a DNA template and an
RNase H that cleaves RNA if, and only if, it is part of an RNA/DNA
duplex. Like many DNA polymerases, RT requires both a template
and a primer; nucleotides are added sequentially to the 3= end of
the primer strand by the polymerase activity of RT. During nor-
mal polymerization, the end of the growing primer strand is at the
primer (P) site, and the incoming deoxynucleoside triphosphate
(dNTP) binds at the nucleoside (N) site. When the polymerase
adds a dinucleotide monophosphate (dNMP) to the 3= end of the
primer strand, inorganic pyrophosphate (PPi) is released. Imme-
diately after incorporation of a nucleotide, the 3= end of the primer
1 strand temporarily resides in the N site; translocation moves
the end of the primer from the N site to the P site, which allows the
cycle to be repeated (1–6).
AZT was the first drug used to treat HIV-1 infections. Al-
though it is no longer the first option for therapy, the WHO still
recommends AZT-containing therapies for those who cannot use
the first option (tenofovir disoproxil fumarate [TDF] plus lami-
vudine [3TC] {or emtricitabine [FTC]} plus efavirenz [EFV]) (see
http://www.who.int/hiv/pub/guidelines/arv2013/intro/rag/en
/index4.html). AZT is a member of the larger class of nucleo-
side analog reverse transcriptase inhibitors (NRTIs). After be-
ing taken up by cells, AZT is converted into the triphosphate
form (AZTTP) by cellular kinases. AZTTP is a dNTP analog
that binds to the RT/template/primer complex and is incorpo-
rated into the growing viral DNA primer by RT. Like other
NRTIs, AZT lacks the 3=-OH group needed for the addition of
the next dNTP; the incorporation of AZT monophosphate
(AZTMP) blocks the synthesis of viral DNA. Early studies iden-
tified a number of amino acid substitutions in HIV-1 RT that
can contribute to AZT resistance in patients undergoing AZT
therapy. These RT mutations include M41L, D67N, K70R,
L210W, T215Y/F, and K219Q/E/N (7–10). Most patients
treated with AZT who develop resistance have viruses that
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carry a subset of these AZT resistance mutations; some combi-
nations of these mutations are commonly seen together. One
pathway is centered on the T215Y mutation, which is often
found in association with the M41L and L210W mutations. The
other common pathway involves various combinations of the
D67N, K70R, T215F, and K219Q/E/N mutations (11, 12). In
this report, we focused on the first set of mutations (T215Y,
M41L, and L210W). We are interested in why different second-
ary mutations are selected in these two pathways.
A number of NRTI resistance mutations are known to act by
reducing the binding and incorporation of an NTRI triphosphate
(NRTITP) relative to normal dNTPs. This type of mutation (col-
lectively referred to as “exclusion mutations”) can be either active,
if, for example, there is a direct steric clash between the amino acid
substitution and the incoming inhibitor, e.g., when the M184V/I
mutations cause a steric clash with the oxathiolane ring of 3TC
triphosphate (3TCTP), or passive, in which differences in the in-
teractions of the normal dNTPs and the NRTITPs with the mutant
RT favor the incorporation of the normal dNTPs over the analog
(e.g., Q151M and K65R) (3–5).
Although some other mechanisms were initially proposed, it is
now clear that the most common AZT resistance mutations cause
enhanced excision of AZTMP after it has been incorporated into
the growing viral DNA (1, 5, 6). The AZTMP moiety is removed
from the end of the primer by using an ATP-dependent pyrophos-
phorolysis mechanism that is related to, but distinct from, polym-
erization reactions run in reverse (2-4, 9). ATP-dependent exci-
sion removes the AZTMP from the 3= end, freeing the viral primer
strand so that DNA synthesis can continue. The amino acid sub-
stitution T215F/Y and the accompanying mutations enhance the
ability of RT to excise AZTMP. The development of an ATP-
excision-dependent AZT resistance mechanism is specific for
HIV-1 RT; HIV-2 RT uses a different AZT resistance mechanism
(13, 14). Because excision is related to polymerization run in re-
verse, mutations in HIV-1 RT that affect excision can also affect
polymerization; one of the reasons for analyzing these mutations
in more detail is to try to better understand how drug resistance
mutations affect these two related processes.
Structural and modeling studies have shown that the T215Y
mutation is one of two (with K70R) primary AZT resistance mu-
tations (2–5). AZT-resistant HIV-1 RT transfers the AZTMP from
the end of the DNA primer to the -phosphate of the ATP, form-
ing a dinucleoside tetraphosphate and producing a free 3=-OH
group at the end of the primer strand (Fig. 1A) (2–4). There are
biochemical data (11, 15, 16), together with the structures of the
excision product bound to RTs of the wild type (WT) and the AZT
resistance variant that has been designated AZT-R (2), that sup-
port the idea that ATP-mediated excision is the mechanism that
underlies the common form of AZT resistance. These AZT resis-
tance mutations do not affect the incorporation of AZTTP by
FIG 1 Structure of the region near the HIV-1 RT polymerase active site that is involved in AZT resistance. (A) Structure of the region near the polymerase active
site of an AZT-resistant HIV-1 RT (AZT-R) containing the dinucleoside tetraphosphate AZTppppA bound to the RT (2). - stacking between Y215 and the
adenine ring stabilizes the binding of the ATP moiety to the mutant RT. The AZTMP has been removed from the end of the primer in an ATP-mediated excision
reaction, but the reaction product has not yet been released. The L210W and M41L mutations do not appear to make contact with the ATP moiety, suggesting
that they may facilitate the excision reaction indirectly. L210W has been modeled into the structure and is located behind the T215Y mutation on the opposite
side of the ATP moiety. It is possible that L210W may interact with T215Y to enhance - stacking with the adenine ring. The L residue of the M41L mutation
is deeper in the RT structure than the WT M residue and does not appear to interact with the substrate directly. (B) Location and orientation of the Y215 side chain
in different RT structures. In the apo form of RT, the side chain appears to interact with P217 and is tucked away from the cleft between the finger and thumb
subdomains. When the dinucleoside tetraphosphate is bound, the tyrosine side chain (Y215) rotates away from P217 into an orientation that can interact with
the ATP moiety. The two structures are compared in the far right diagram. (C) Interactions of M41L with F116. The leucine side chain is far enough away from
the dinucleoside tetraphosphate that it is unlikely to interact directly with this substrate. However, the leucine (L41) side chain could interact with F116, which
is near the azido group of the AZT moiety. Nonetheless, this interaction does not appear to alter the position of F116.
HIV-1 RT AZT Resistance
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HIV-1 RT. For the sake of completeness, we have repeated these
assays, using both RNA and DNA templates, for the AZT resis-
tance mutations described in this work (see Results). We also
point out that due to microscopic reversibility, mutations in RT
cannot preferentially speed up the excision of AZTMP from the
end of the viral DNA using pyrophosphate as an excision substrate
without also causing an equivalent increase in the rate at which
AZTTP is incorporated. This means that an excision-based mech-
anism that uses PPi as the excision substrate cannot lead to resis-
tance (17, 18).
It has also been suggested that AZT resistance mutations do not
primarily affect the binding but rather affect the positioning of
ATP (19). That proposal is not supported by either the biochem-
ical data of Dharmasena et al. (16) or the structural data of Tu et al.
(2). The aromatic side chain of a Y at position 215 interacts with
the adenine moiety of ATP, enhancing the ability of RT to bind the
ATP that is used in the excision reaction (Fig. 1A). The location of
the tyrosine side chain of T215Y is 9.0 Å from the polymerase
active site (Fig. 1A and B). The other primary AZT resistance
mutation in HIV-1 RT, K70R, interacts with the ribose ring and
the alpha phosphate of the ATP involved in the excision reaction.
A tyrosine at position 215 and an arginine at position 70 specifi-
cally interact with a portion of the ATP that does not overlap an
incoming dNTP or the pyrophosphate that is produced when a
dNMP is incorporated. This is why these mutations, which help
HIV-1 RT bind ATP in the excision reaction, can selectively speed
up the excision reaction without affecting the incorporation of
AZTTP. It is also important to point out that crystal structures
show that the WT form of HIV-1 RT does not have any interac-
tions with the ribose ring, the nucleobase, or the alpha phosphate
of ATP. Thus, the structural data show how the interactions made
by the T215Y and K70R mutations allow AZT-resistant RTs to
better bind ATP (2).
Although the role of a Y residue at position 215 is clear, the
roles played by the accompanying secondary mutations are far less
certain. As mentioned above, M41L is often associated with
T215Y, and the addition of the M41L mutation to T215Y reduces
the susceptibility of the virus to AZT compared to that with T215Y
alone. However, M41L is not in a position where it can interact
directly with the ATP that is involved in the excision reaction (Fig.
1A and C) (2), nor is it located near the T215Y mutation; rather,
M41 is buried deeper in the RT structure. The leucine side chain of
L41 interacts with Phe116 (4.0-Å separation), which is part of the
dNTP-binding pocket located near the 3=-OH group of an incom-
ing dNTP (Fig. 1C). The side chain of F116 is also near the azido
side chain of an AZTMP on the end of the primer strand, suggest-
ing that the effects of a leucine side chain at position 41 could be
transmitted to the AZT group through F116 (2, 20). Because the
excision reaction is closely related to the polymerization reaction
run in reverse, an incorporated NRTI monophosphate (NRTIMP)
must be located at the N site to be excised. The long azido
group of AZTMP causes the 3= end of the primer to preferentially
reside at the N site, which makes it a better substrate for excision
than other NRTIMPs. It is thought that the M41L mutation may
help stabilize the binding of an AZTMP-terminated primer in the
N site, facilitating the excision reaction (Fig. 1C). The L210W
mutation has not been included in any of the reported structural
studies. However, the L210W mutation reduces the susceptibility
of HIV to AZT in the presence of the T215Y mutation (7, 21, 22).
The indole ring of a tryptophan side chain at W210 has been
predicted to be in a position where it could interact with the ty-
rosine side chain of the T215Y mutant, potentially enhancing the
aromatic stacking of Y215 with ATP (22). Based on this logic, the
location of L210W has been modeled into the known AZT-R
structure in Fig. 1A. It has been suggested that L210W may act as
an anchor, preventing any large-scale movements of T215Y that
would allow the side chain of Y215 to move away from the ATP-
binding site, which could improve ATP binding. T215Y has a neg-
ative impact on the polymerase activity of RT. We show here that
not only do M41L and L210W improve the ATP-dependent
excision reaction, they also, to some degree, compensate for the
negative impact of the T215Y mutation on the polymerase ac-
tivity of RT.
MATERIALS AND METHODS
Preparation of HIV-1 RT. The open reading frames encoding wild-type
HIV-1 RT and each of the RT mutants were cloned into a plasmid con-
taining the HIV-1 protease (PR) open reading frame, as previously de-
scribed (14, 17). The RT coding region was derived from HIV-1 strain
BH10 (GenBank locus HIVBH102). The plasmid is based on the expres-
sion vector pT5m and was introduced into Escherichia coli strain
BL21(DE3)(pLysE). Induction with isopropyl--D-thiogalactopyrano-
side (IPTG) (200.0l of 1.0 M) causes the bacteria carrying the plasmid to
express both RT and PR. After 2.0 h of incubation, approximately half of
the RT in the bacteria is converted into the small (p51) subunit by PR. The
bacteria were collected by centrifugation, and the cells were frozen at
70°C. The HIV-1 RT heterodimer was purified as previously described
(14, 17).
We performed assays to measure the ability of the WT and mutant
enzymes to extend a primer on an RNA or a DNA template if the RTs are
restricted to a single round of binding and DNA extension (processivity
assay) and the ability of the RT to extend a primer if additional rounds of
binding and extension are permitted (polymerase assay). Because the mu-
tations can affect the ability of RT to bind the dNTP substrates, we also
performed polymerase assays with low concentrations of dNTPs, and we
performed kinetic assays to make these comparisons quantitative. Al-
though we did not expect that the AZT resistance mutations, which are in
the polymerase domain, would affect RNase H activity, we performed
RNase H assays to show that there was no effect. In terms of the effects of
the mutations on AZT resistance, we showed that the mutations did not
affect the incorporation of AZTTP on either an RNA or a DNA template
(NRTITP inhibition assay), and we used excision-extension assays to
measure the impact that the mutations had on AZTMP excision at both
what is usually considered to be the normal level of ATP in a growing cell
(3 mM) and a lower concentration, which might be found in a resting cell
(0.6 mM).
Processivity andpolymerase assays.The processivity and polymerase
assays were previously described (14, 17). In brief, the 47 sequencing
primer (5=-CGCCAGGGTTTTCCCAGTCACGAC-3=) (New England
BioLabs) was 5=-end labeled with [-32P]ATP and T4 polynucleotide ki-
nase. After purification, the labeled primer was annealed to 1.0 g of
single-stranded M13mp18 DNA for each sample to be assayed by heating
and slow cooling. An RNA transcript [generated from a plasmid that
contains the HIV-1 PPT, long terminal repeat (LTR), and primer-bind-
ing-site sequences (sense strand)] was synthesized by using the T7
MEGAScript kit (Ambion) and a plasmid containing sequences derived
from pNL4-3. A synthetic DNA oligonucleotide (Biosource) complemen-
tary to the primer-binding-site sequence (5=-GTCCCTGTTCGGGCGCC
A-3=) was 5=-end labeled and then annealed to the RNA template.
The RNA template/labeled DNA primer or DNA template/labeled
DNA primer combination was resuspended in a mixture containing 25.0
mM Tris-HCl (pH 8.0), 75.0 mM KCl, 8.0 mM MgCl2, 100.0g of bovine
serum albumin (BSA) per ml, 10.0 mM CHAPS {3-[(3-cholamidopro-
pyl)-dimethylammonio]-1-propanesulfonate}, and 2.0 mM dithiothrei-
Boyer et al.
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tol (DTT). One microgram of purified wild-type RT or an RT variant was
added to each tube and allowed to bind to the labeled template/primer for
2 min. Extension was initiated by the addition of dNTPs, to give a final
concentration of 10.0 M each. For the processivity assays, 0.5 U of
poly(rC)·oligo(dG) per ml was added to the reaction mixtures after the
RT-binding step but before the addition of the dNTPs. The polymerase
assay mixtures do not contain this “cold trap.” Poly(rC)·oligo(dG) pre-
vents RT from rebinding to the labeled primer by binding RT after it
disassociates from the labeled template/primer. The reactions were al-
lowed to proceed at 37°C for 10 min and were then halted by the addition
of EDTA to the mixtures. The samples were precipitated by the addition of
2 volumes of ethanol. The samples were fractionated by electrophoresis
on a 6.0% polyacrylamide gel, and the gel was autoradiographed.
Low-dNTP extension assay. The low-dNTP extension assay was de-
scribed previously (14, 17). Briefly, the DNA template/DNA primer and
RNA template/DNA primer combinations were generated as described
above. For each sample, 1.0g of wild-type RT or an RT variant was added
to the labeled template/primer in a mixture containing 25.0 mM Tris-Cl
(pH 8.0), 75.0 mM KCl, 8.0 mM MgCl2, 2.0 mM DTT, 100.0 g of BSA
per ml, and 10.0 mM CHAPS. The reaction mixture was supplemented
with 0.1, 0.2, 0.5, or 1.0 M (each) dATP, dCTP, dGTP, and dTTP. The
reactions were allowed to proceed at 37°C for 15 min and were halted by
the addition of EDTA to the mixtures. The samples were precipitated by
the addition of 2 volumes of ethanol and fractionated by electrophoresis
on a 6.0% polyacrylamide gel, and the gel was autoradiographed.
AZTMP excision-extension assay. The ATP-dependent excision-ex-
tension assay was done as previously described (14, 17). A synthetic DNA
oligonucleotide (5=-CAGGTCACTGTTCGAGCACCA-3=) (Biosource,
Camarillo, CA) was 5=-end labeled and then annealed to the DNA tem-
plate (5=-GCGCAGTGTAGACAATCCCTAGCTATGGTGCTCGAACA
GTGACCTG-3=) or the RNA template (5=-GCGCAGUGUAGACAAUC
CCTAGCUAUGGUGCUCGAACAGUGACCUG-3=). The 3= end of the
primer was then blocked by the addition of AZTMP, using a purified
HIV-1 RT that contains mutations in the RNase H active site (D443A and
D549A). The underlined A residues in the sequences of the templates
indicate the position in the template that specifies the position at which
AZTMP was added to the primer. After purification of the blocked tem-
plate/primer, the template/primer was incubated with HIV-1 RT or the
RT variant in 50.0 l of a mixture containing 50.0 mM HEPES (pH 7.5);
75.0 mM KCl; 16.0 mM MgCl2; 100.0g of bovine serum albumin per ml;
10.0 mM CHAPS; 10.0 M (each) dATP, dTTP, dGTP, and dCTP; and
the indicated concentrations of the various nucleoside triphosphates
(NTPs) (ChemCyte) for various lengths of time. The reactions were halted
by the addition of EDTA to the mixtures, the salts and nucleosides were
removed by passage through a CentriSpin-10 column (Princeton Separa-
tions), and the template/primer was precipitated by the addition of etha-
nol. The products were fractionated on a 15% polyacrylamide sequencing
gel. The amount of template/primer (blocked and unextended plus de-
blocked and extended) and the amount of full-length product (deblocked
and extended to the end of the template) were determined by using the
PhosphorImager system.
NRTITP inhibition assay. A synthetic DNA oligonucleotide (5=-CAG
GTCACTGTTCGAGCACCA-3=) (Biosource, Camarillo, CA) was 5=-end
labeled and then annealed to the DNA template (5=-GCGCAGTGTAGA
CAATCCCTAGCTATGGTGCTCGAACAGTGACCTG-3=) or the RNA
template (5=-GCGCAGUGUAGACAAUCCCTAGCUAUGGUGCUCG
AACAGUGACCUG-3=). The annealed template/primer was suspended
in 50.0 l of a mixture containing 25.0 mM Tris-HCl (pH 8.0); 75.0 mM
KCl; 8.0 mM MgCl2; 100.0 g of bovine serum albumin per ml; 10.0 mM
CHAPS; and 10.0 M (each) dATP, dTTP, dGTP, and dCTP and then
incubated with 1.0 g of RT in the presence of various concentrations of
the triphosphate form of the analog for 10 min at 37°C. The products were
purified and then fractionated on a 15% polyacrylamide sequencing gel.
The total amount of template/primer (analog-blocked products and full-
length products) and the amount of full-length product (extended to the
end of the template) were determined by using the PhosphorImager sys-
tem. The amount of full-length product in the absence of any NRTITP was
considered 100% activity. The activity with the NRTITPs was normalized
to this value. The percentage of full-length product was calculated by
determining the amount of primer that was extended to the end of the
template and dividing this amount by the amount of all of the extension
products (full-length and NRTIMP-blocked primers).
RNaseH assay.The RNase H assay was previously described (17). The
RNA oligonucleotide was obtained from Dharmacon Research, Inc., and
has the sequence 5=-GGGCCACUUUUUAAAAGAAAAGGGGGGACU
GGAAGGGCUAAUUCACUCAC-3=. This sequence matches the se-
quence of the HIV-1 RNA genome and extends from just 5= of the poly(U)
tract, through the PPT, and into the U3 region. The RNA oligonucleotide
was 5=-end labeled and then annealed to a synthetic DNA oligonucleotide
(5=-GAGTGAATTAGCCCTTCCAGTCCC-3=) by heating and slow cool-
ing. The template/primer was adjusted to give a final concentration of 0.2
M in a mixture containing 25.0 mM Tris-HCl (pH 8.0), 50.0 mM NaCl,
5.0 mM MgCl2, 100.0g of bovine serum albumin/ml, 10.0 mM CHAPS,
and 1 U of Superasin (Ambion)/l. The final reaction mixture volume
was 12.0l. The reactions were initiated by the addition of 35.0 nM RT to
the mixtures, and the mixtures were incubated at 37°C. Aliquots of 2.5 l
were removed at the indicated time points, and the reactions were halted
by the addition of 4.0l gel loading buffer (Ambion) to the mixtures. The
reaction products were fractionated on a 15% polyacrylamide sequencing
gel. Products were visualized by exposure to X-ray film.
Kinetics. A synthetic DNA oligonucleotide (5=-CAGGTCACTGTTC
GAGCACCA-3=) (Biosource, Camarillo, CA) was 5=-end labeled and then
annealed to the appropriate DNA template (depending on the dNTP be-
ing tested) (5=-GCGCAGTGTAGACAATCCCTAGCTNTGGTGCTCGA
ACAGTGACCTG-3=). To allow different dNTPs to be tested, several tem-
plates were prepared. They differed as to the nucleotide present at the
underlined position labeled N in the sequence. The template/primer
(T/P) was adjusted to a final concentration of 25.0 nM in 50.0 l of a
mixture containing 25.0 mM Tris-HCl (pH 8.0), 75.0 mM KCl, 8.0 mM
MgCl2, 100.0 g of bovine serum albumin per ml, and 10.0 mM CHAPS.
The variable substrate (dNTP) was added at concentrations ranging from
1.25 to 40.0M. The reaction was initiated by the addition of RT to a final
concentration of 0.1 nM. Reaction mixtures were incubated for 10 min at
37°C. The products were purified and then fractionated on a 15% poly-
acrylamide sequencing gel. The amount of primer (unextended primer
and the reaction product of primer plus 1 nucleotide [primer  1]) was
determined by using the PhosphorImager system. The amount of
primer  1 was divided by the amount of total primer (primer and
primer  1) to determine the fraction of primer  1 that was generated
from the dNTP substrate in 10 min with the given amount of RT. The
various kinetic values were calculated from these data.
RESULTS
AZTMP excision/extension assays. We analyzed the abilities of
WT RT and three different mutants (the T215Y mutant, the
M41L/T215Y double mutant, and the M41L/L210W/T215Y triple
mutant) to use ATP to remove AZTMP from the 3= end of the
primer and to extend the primer to the end of the template strand.
As described in Materials and Methods, AZTTP was present in
these assay mixtures at a concentration of 1.0 M so that during
the extension of the primer strand, there was the possibility that
AZTMP would be incorporated, rather than the normal dTTP
substrate. The general protocol, which is shown in Fig. 2A, was
designed to mimic what occurs during the conversion of the sin-
gle-stranded viral RNA genome into double-stranded DNA in an
infected cell. When the ATP was present at a concentration of 3.0
mM, WT HIV-1 RT inefficiently removed the AZTMP blocking
group and extended the primer. This concentration of ATP is the
standard concentration used for excision assays and was chosen
HIV-1 RT AZT Resistance
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because it is believed to be similar to the concentration that is
present in dividing cells (15, 23, 24). The inefficient removal of
AZTMP was evident in experiments done with either a DNA tem-
plate (Fig. 2B) or an RNA template (Fig. 2C), although the amount
of full-length product was smaller in the experiments done with
the RNA template. The T215Y RT variant had an enhanced ability
(2-fold at the 60-min time point) to excise the AZTMP blocking
group and fully extend the primer with either template, relative to
the WT. Both the M41L/T215Y and M41L/L210W/T215Y mutant
RTs were able to remove AZTMP and extend the primer even
more efficiently than the RT carrying T215Y alone (Fig. 2B and C).
However, in these assays, the M41L/L210W/T215Y mutant and
the M41L/T215Y double mutant behaved similarly; there was no
apparent advantage to having the L210W mutation present.
HIV-1 can replicate in nondividing cells, where the concentra-
tions of ribonucleoside triphosphates are lower than those in di-
viding cells, and based on the available data, we reduced the level
of ATP to 0.6 mM and repeated the assays (15, 25) (Fig. 2D and E).
In these assays, the M41L/L210W/T215Y mutant generated a
higher level of full-length product in the excision/extension reac-
tion, using a DNA template, than did either the M41L/T215Y
double mutant (8% more at 60 min) or the T215Y mutant (2-
fold more at 60 min). Results obtained by using an RNA template
showed that the triple mutant was better at excision-extension
than the T215Y mutant (slightly more than 2-fold more at 60
min). The results are less clear when the M41L/L210W/T215Y
mutant is compared to the M41L/T215Y mutant. The level for the
triple mutant was consistently higher, but the difference was
small, only a few percentage points. It is not clear whether this
difference would be significant for the replication of the virus.
Thus, the addition of the L210W mutation appears to improve the
ability of the M41L/L210W/T215Y mutant RT to use relatively
low levels of ATP in the excision reaction. As shown in Fig. 1B,
Y215 stacks with P217 in the absence of ATP and stacks with the
adenine base of a bound ATP. In the T215Y mutant, the side chain
of Y215 is likely to switch between the two orientations in the
process of association and dissociation of ATP; however, the side
chain of W210 (in the M41L/L210W/T215Y mutant) would stack
with the side chain of Y215 and stabilize it in the ATP-bound
conformation, which would provide better access for ATP and
help it to bind when ATP is present at lower concentrations. Sim-
ilar results were obtained in reactions in which UTP, GTP, or CTP
was used as the excision substrate instead of ATP, although the
overall level of excision varied depending on which NTP was used
for the assays (see Fig. S1 to S3 in the supplemental material). The
use of GTP generated approximately the same amount of full-
length product as that with ATP; CTP and UTP tended to be less
effective at producing the full-length product. This may reflect the
fact that the nucleobases of ATP and GTP have two aromatic rings,
while CTP and UTP have one. The interaction of the aromatic side
FIG 2 Comparison of the abilities of the various mutant RTs to excise AZTMP from the end of the blocked primer and extend the primer in the presence of
AZTTP. (A) General outline of the experimental protocol. The template can be varied at the designated “N” site so that any NRTITP can be tested for its ability
to be excised; however, in the experiments described in the text, the “N” is an “A” so that AZTMP will be incorporated. The asterisk indicates the presence of the
32P end label on the primer. The end of the primer is blocked with the desired NRTIMP (in the experiments described in the text, the analog is AZTMP, which
is represented by the stop sign). Either a DNA or an RNA template can be used in the reaction. The blocked template/primer is purified and used as a substrate
for the mutant RTs in the presence of the indicated concentrations of ATP, 1.0M AZTTP, and 10.0M each dNTP at 37°C for the indicated amounts of time.
The reactions are stopped, the template/primer is purified, and the products are fractionated by PAGE on a 15% gel. The amount of full-length product
(extension of the primer to the end of the template) is measured by using the PhosphorImager system and is expressed as a percentage of the total amount of
primer. (B and C) Ability of WT RT and the T215Y, M41L/T215Y, and M41L/L210W/T215Y mutants to excise AZTMP from the end of the primer using 3.0 mM
ATP and extend the primer on either a DNA template (B) or an RNA template (C). (D and E) Excision/extension by these mutants with 0.6 mM ATP for a DNA
template (D) and an RNA template (E).
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chain of a tyrosine at position 215 may be better with purines,
which present a larger aromatic surface, than with pyrimidines.
To better understand the contribution of the secondary muta-
tions, we constructed a mutant that does not contain M41L
(L210W/T215Y); this allowed us to study the effects of these two
mutations without the influence of M41L. We also included the
AZT-resistant variant AZT-R (M41L/D67N/K70R/T215Y/K219Q),
which we have used in previous studies and which was the mutant
used to generate the RT structure discussed above. Although all of
the mutations in AZT-R can contribute to AZT resistance (7–10),
the particular combination of mutations present in AZT-R does
not appear to be commonly selected in patients. A search of the
Stanford Database for all viruses in which the RT carries T215Y
shows that the M41L mutation is also present 83.2% of the time,
D67N is present 48.3% of the time, K70R is present 12.8% of the
time, and K219Q is present 5.3% of the time. However, there are
other mutations found at position 219: K219R is present 6.8% of
the time that T215Y is present, K219E is present 6.7% of the time,
and K219N is present 8.9% of the time. Thus, viruses that contain
the M41L, D67N, and T215Y mutations are commonly seen in
patients; however, viruses that also carry the two additional mu-
tations present in the AZT-R RT are less common. The behavior of
these new mutants was compared to those of WT RT and the
M41L/L210W/T215Y triple mutant. As shown in Fig. 3A, the
L210W/T215Y double mutant was equivalent, in the excision ex-
tension assay, to the M41L/L210W/T215Y triple mutant with a
DNA:DNA template/primer, showing that the L210W mutation
can enhance the ability of the T215Y mutant RT to excise AZTMP.
However, with an RNA:DNA template/primer, the L210W/T215Y
double mutant RT was not much better in the excision/extension
assay (Fig. 3B) than an RT carrying T215Y alone (Fig. 2C). For
both templates, AZT-R had the highest level of excision/extension
activity (Fig. 3).
There have been some claims that for this group of mutations,
AZT resistance involves a reduction in the ability of the mutant RT
to incorporate AZTTP (26, 27). To confirm that excision was the
only resistance pathway for these mutants, the WT and T215Y,
M41L/T215Y, and M41L/L210W/T215Y mutant RTs were tested
for their ability to incorporate AZTTP. Both an RNA template and
a DNA template were tested. The DNA template is single-stranded
M13mp18 DNA, and the RNA template contains sequences from
the polypurine track, long terminal repeat, and primer binding
site (PPT-LTR-PBS) of HIV-1. A labeled primer was extended in
the presence of all four dNTPs and various concentrations of
AZTTP. The susceptibilities of all of the RTs to inhibition by
AZTTP were similar for both templates, indicating that none of
the mutations had a significant effect on the ability of RT to incor-
porate AZTTP (Fig. 4A and B).
Polymerase assays. To determine how the various mutations
affected the enzymatic activities of the WT and mutant RTs, sev-
eral assays were performed. Because resting cells generally have
lower dNTP levels than do actively growing cells (15, 25), the
ability of the RTs to incorporate relatively low concentrations of
dNTPs was tested by using both a DNA template and an RNA
template. When the template was DNA, the T215Y RT mutant was
less able to extend the primer than was WT RT. The defect in
extension was apparent at all of the concentrations of dNTPs that
were tested (Fig. 5A). The M41L/T215Y double mutant was better
able to extend the primer than was the T215Y mutant but was still
somewhat defective compared to WT RT. Thus, the addition of
the M41L mutation appears to compensate to some degree for the
reduced ability to incorporate dNTPs caused by the T215Y muta-
tion. The addition of the L210W mutation to the double mutant
(yielding the M41L/L210W/T215Y triple mutant) improved
dNTP incorporation to a level similar to that of the WT (Fig. 5A).
Similar results were obtained when the assays were repeated by
FIG 3 Comparison of the abilities of additional mutant RTs to excise AZTMP from the end of the blocked primer and extend the primer in the presence of
AZTTP. Excision/extension reactions were carried out by WT RT and the L210W/T215Y, M41L/L210W/T215Y, and AZT-R (M41L/D67N/K70R/T215Y/
K219Q) mutants on either a DNA (A) or an RNA (B) template, as described in the legend of Fig. 2 and in Materials and Methods.
FIG 4 Ability of WT RT and the T215Y, M41L/T215Y, and M41L/L210W/
T215Y mutants to incorporate AZTTP in the presence of normal dNTPs. The
RTs were challenged with a range of AZTTP concentrations while the concen-
tration of dNTPs was held constant. If the mutant RTs differ in their ability to
bind and incorporate AZTTP, the amount of full-length product will decrease
at a rate that differs from that of WT RT. Temp(UA) refers to the fact that the
first 2 nucleotides in the template after the double-stranded region are
uracil-adenine.
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FIG 5 Comparison of the polymerase activities of the WT and mutant RTs. A 5=-end-labeled primer was annealed to single-stranded M13mp18 DNA (A, B, E,
and F) or PPT-LTR-PBS RNA (C, D, G, and H). (A, C, E, and G) In the low-dNTP assay, RT was allowed to extend the labeled primer in the presence of
suboptimal levels of dNTPs (0.1, 0.2, 0.5, and 1.0 M each dNTP) for 15 min at 37°C. (B, D, F, and H) For the processivity assay, the 5=-end-labeled primer was
annealed to single-stranded M13mp18 DNA or PPT-LTR-PBS RNA. RT was allowed to bind in the absence of dNTPs. dNTPs (20 M each) and a “cold trap”
[poly(rC)·oligo(dG)] were added to initiate the reaction, and the reaction mixtures were incubated at 37°C. The cold trap limits the polymerase reaction to one
cycle of extension. The DDDP or RDDP reaction had no trap, and multiple rounds of binding and polymerization will occur. nt, nucleotide.
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using RNA as a template (Fig. 5C). The L210W/T215Y and AZT-R
mutants showed much greater defects in polymerization than did
the other RT variants, and both of these variants showed defects in
polymerization with either a DNA or an RNA template (Fig. 5E
and G).
Processivity assays and related DNA-dependent DNA poly-
merase (DDDP) assays were performed with higher levels of
dNTPs (25.0 M each) than those in the polymerization assays
described above. These assays differ in that the processivity assays
include a trap that limits RT to a single round of binding and
FIG 5 continued
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polymerization. Once RT falls off the template/primer, it binds to
the trap. The trap is omitted in the corresponding DDDP assays.
With a DNA template, the T215Y mutant and the M41L/T215Y
double mutant caused only a very modest defect in the processiv-
ity assay and may have had a modestly greater effect in the DDDP
assay (Fig. 5B). These results suggest that a portion of the defect
seen with the mutants is probably caused by an inability to bind
and incorporate dNTPs efficiently when they are present at low to
normal concentrations (Fig. 5A). The processivity assays were also
done with an RNA template (Fig. 5D), and the results were similar.
The mutations caused only modest defects in polymerase activity
(Fig. 5D). A gel shift assay was used to compare the abilities of WT
RT and the T215Y, M41L/T215Y, and M41L/L210W/T215Y mu-
tant RTs to bind a DNA:DNA template/primer. The results
showed that all of the RTs bound a template/primer with similar
efficiencies (see Fig. S4 in the supplemental material). These data
reinforce the idea that the primary problem with the polymerase
activity of these mutant RTs is an impairment of their ability to
bind and/or effectively incorporate dNTPs at low to normal con-
centrations. In contrast, the L210W/T215Y and AZT-R mutant
RTs showed an obvious defect in the DDDP assay, the RNA-de-
pendent DNA polymerase (RDDP) assay, and both processivity
assays, which showed that relatively high concentrations of dNTPs
were not enough to rescue the polymerization defects of these
mutants (Fig. 5F and H). WT RT and the T215Y, M41L/T215Y,
and M41L/L210W/T215Y mutants were also tested to determine if
the mutant RTs had any defects in their RNase H activities. There
were no significant difference in the RNase H activities of the RT
mutants and the WT enzyme, suggesting that the RNase H active
site is not affected by the alterations around the polymerase active
site (see Fig. S5 in the supplemental material).
Kinetics. There are several difficulties that can be encountered
when RT, or other DNA polymerases, is tested using steady-state
kinetics. There are two substrates involved in the reaction, the
template/primer and the dNTPs. The presence of excess template/
primer can make the reaction pseudo-first order; i.e., excess tem-
plate/primer acts to make the reaction appear to have only one
reactant since the second substrate is not limiting. In addition, RT
will encounter a wide variety of sequences when it copies either an
RNA or a DNA template, and the efficiency with which RT incor-
porates and excises AZTMP varies depending on the sequence of
the template (28). Finally, because RT copies single-stranded RNA
and DNA template overhangs, the structure of the single-stranded
portion of the template can affect the reaction. Despite these ca-
veats, kinetic analysis using a template with a well-defined se-
quence and a variable concentration of one of the dNTPs can give
useful insights into how the RT interacts with its substrates. The
overall kinetics diagram and reaction substrates are shown in Fig.
6. Reactions were run under steady-state conditions. Vmax and kcat
were derived from the same data; Vmax is included to make the
comparison of Km values simpler (described below). Vmax is the
maximal amount of product (P), in this case a primer extended by
1 nucleotide, that can be generated per unit of time. kcat is the
amount of product generated in a unit of time per amount of
enzyme (Vmax/ET) and is often referred to as the turnover number.
Although the units are in seconds, the unit nanomolar P/nanomo-
lar RT is implied, and kcat refers to the number of reactions that
each active site catalyzes per unit of time when the enzyme is fully
saturated. When dTTP was the substrate, all of the mutants had a
lower kcat than that of WT RT, although the kcat values for the
M41L/T215Y and M41L/L210W/T215Y mutants were higher
than that for the T215Y mutant (Table 1 and Fig. 6). The T215Y
mutation also decreased the kcat with dATP and dGTP. The kcat
values with dCTP are closer to those for WT RT. The values for the
M41L/T215Y and M41L/L210W/T215Y mutants are similar to
those for WT RT with dATP, dGTP, and dCTP. Therefore, under
conditions in which the enzyme is saturated, only the T215Y mu-
tant caused a significant decrease in the ability of RT to synthesize
DNA; i.e., this mutant enzyme has a lower turnover rate than that
of the WT, and the addition of the M41L/L201W mutation helps
to rescue the efficiency of the polymerase.
Km is the Michaelis constant and represents the amount of
substrate (dNTP) needed to reach one-half Vmax. Because Km is a
measure of the amount of substrate needed for efficient catalysis
to occur, it is related to the ability of the enzyme to bind the
substrate; thus, it is possible to have two RTs with similar Vmax
values that require different amounts of the substrate to reach the
Km. All of the mutants have Vmax values that are lower than that of
the WT for dTTP; in addition, their Km values vary. The T215Y
mutant has the highest Km value, suggesting that this mutant
needs more dTTP than does the WT to reach half-maximal veloc-
ity; the M41L/L210W/T215Y mutant also has a significantly
higher Km for dTTP than does the WT. The M41L/T215Y mutant
has a Km value for dTTP that is similar to that of the WT. The
T215Y mutant also has an increased Km value compared to that of
WT RT for dCTP and dGTP. The M41L/T215Y and M41L/
L210W/T215Y mutants have Km values similar to those of the WT
for dATP and dCTP, but their Km values for dGTP are slightly
increased.
The catalytic efficiency (kcat/Km ratio) of an enzyme is used as a
measure of its overall ability to use the substrate. The catalytic
efficiencies of the RTs have been calculated based on their ability
to incorporate dNTPs, and the value for WT RT was set to 1.0.
Overall, the T215Y RT mutant is the least efficient enzyme for all
dNTP substrates (Table 1). The addition of M41L to either the
T215Y mutant alone or the L210W/T215Y double mutant im-
proved the catalytic efficiency of the enzyme. However, all of the
mutants were less efficient than the WT, particularly with the
dTTP substrate. These data indicate that the mutations interfere
with the ability of the RT to bind and/or catalyze the incorporation
of dNTPs; however, the effects were somewhat different not only
for the different mutant RTs but also for the various dNTPs. In
general, the presence of the M41L and L210W mutations compen-
sated, to some extent, for the deleterious effects of the T215Y
mutation on the polymerase activity of HIV-1 RT.
To see how well our data conform to what has been reported
for patients, we examined the Stanford Database (http://hivdb
.stanford.edu/) using an approach similar to that used by Yahi et
al. (11). This was done by asking whether the amino acid substi-
tution(s) of interest is present in the sequences of viruses isolated
from patients. We first asked whether these mutations were
strongly associated with a particular treatment history. We ana-
lyzed data reported between 2000 and 2005. Of the patients whose
viruses had the T215Y mutation (and the drugs being used for
therapy were known), 90.8% had been treated with AZT. Because
stavudine (d4T) (which was used clinically but is no longer given
to patients) also selects for similar excision mutations, we also
checked for treatment with this drug (29). A total of 98.4% of
patients who developed the T215Y mutation were treated with
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either AZT or d4T. Thus, in the absence of d4T therapy, the exci-
sion mutation(s) is strongly associated with AZT therapy.
We also asked about the associations of the other amino acid
substitutions that we analyzed. As shown in Table 2, in viral ge-
nomes (the initial search included all of the subtypes in the data-
base) in which there was a T215Y mutation present (100% of
sequences), an M41L mutation was also present 84.5% of the time,
and an L210W mutation was present 62.3% of the time. For the
subtype B genomes alone, an M41L mutation was also present
86.5% of the time, and L210W was present 66.4% of the time. This
indicates that M41L is more important for the functioning of an
AZT-resistant RT that carries the T215Y mutation than L210W.
This matches what our assays showed: in the presence of a T215Y
mutation, M41L increased both excision and polymerase activi-
ties, and L210W did not greatly increase excision and decreased
polymerase activity when combined with T215Y. This suggests
that for the L210W mutation to have a positive effect on RT, M41L
might already have to be selected. Indeed, when both L210W and
T215Y are present, M41L is also present 94.6% of the time. To be
sure that these relationships were not affected by the HIV subtype,
the analysis was done by using sequences of several different sub-
types that were taken from the database individually. Although
there was some variation, the frequencies with which the various
mutations accompanied each other were similar for the various
subtypes (see Table S1 in the supplemental material). Therefore,
M41L appears to be the linchpin that allows for the selection of the
L210W mutation, giving rise to the M41L/L210W/T215Y variant.
M41L appears to increase the ability of the T215Y mutant to excise
TABLE 1 Results obtained from kinetic reactionsa
Substrate and enzyme
Mean Vmax
(nM dNTP min1)	 SD
Mean Km
(M dNTP)	 SD
Mean kcat
(s1)	 SD kcat/Km Ratio
TTP
WT 0.44 	 0.04 0.92 	 0.05 0.073 	 0.007 0.079 1.0
T215Y 0.11 	 0.02 2.12 	 0.04 0.018 	 0.003 0.009 0.11
41/215 0.16 	 0.03 0.80 	 0.03 0.027 	 0.005 0.034 0.43
41/210/215 0.23 	 0.01 1.53 	 0.07 0.038 	 0.002 0.025 0.32
dATP
WT 0.68 	 0.03 0.63 	 0.02 0.113 	 0.005 0.179 1.0
T215Y 0.43 	 0.04 0.54 	 0.03 0.072 	 0.007 0.133 0.74
41/215 0.69 	 0.05 0.61 	 0.04 0.115 	 0.008 0.189 1.06
41/210/215 0.68 	 0.04 0.54 	 0.03 0.113 	 0.007 0.209 1.17
dCTP
WT 0.31 	 0.04 1.07 	 0.07 0.052 	 0.007 0.049 1.0
T215Y 0.29 	 0.04 2.64 	 0.10 0.048 	 0.007 0.018 0.36
41/215 0.34 	 0.02 1.23 	 0.06 0.057 	 0.003 0.046 0.93
41/210/215 0.30 	 0.03 1.07 	 0.05 0.050 	 0.005 0.046 0.93
dGTP
WT 0.34 	 0.03 0.83 	 0.03 0.057 	 0.005 0.069 1.0
T215Y 0.22 	 0.03 1.69 	 0.04 0.037 	 0.005 0.022 0.32
41/215 0.32 	 0.01 1.55 	 0.03 0.053 	 0.002 0.034 0.49
41/210/215 0.33 	 0.04 1.12 	 0.04 0.055 	 0.007 0.049 0.71
a Kinetic analysis was done as described in the legend of Fig. 6. The variable substrate [S] is the concentration of the dNTP being tested. WT refers to the wild-type RT, while T215Y
contains only that mutation. 41/215 and 41/210/215 refer to RT mutations containing M41L/T215Y or M41L/L210W/T215Y, respectively. The product [primer 1] is technically
the concentration of PPi released from the reaction, but this is equal to the amount of primer extended by one nucleotide (primer 1). [E] is the amount of enzyme (0.1 nM RT).
The use of the various rate constants is explained in the text. Vmax is nanomolar primer 1 per minute. Km is the Michaelis-Menten constant in micromolar dNTP. The amount of
S needed to obtain one-half Vmax is calculated as follows: Km
 (k1  k2)/k1. kcat is the “turnover number” per second, calculated as follows: kcat 
 Vmax/[E]t. kcat replaces the
rate-limiting constant between ES and E plus P. The kcat/Km value is considered to be a measure of catalytic efficiency. Since these values can be hard to compare to each other, the
last column (labeled Ratio) has the catalytic efficiency set at 1.0 for the WT RT. The other catalytic efficiencies are normalized to this value.
FIG 6 (Right) Diagram of the kinetic reaction. The primer is labeled at the 5= end and then annealed to the appropriate template, depending on which dNTP is
being tested (in this diagram, dTTP is shown as being added where the template contains an “A”). (Left) Diagram indicating the various reactants and rate
constants during the polymerization process. The reaction mixture contained 25.0 nM labeled template/primer (T/P) and 0.1 nM the appropriate RT. The
reaction was initiated by the addition of the dNTP. Reactions were performed at 37°C for 10 min, the reactions were stopped, the T/P was purified, and the
samples were fractionated on a 15% PAGE gel. The products were analyzed on a PhosphorImager instrument. The variable substrate (S) is the concentration of
the dNTP being tested. P is technically the concentration of PPi released from the reaction, but this is equal to the amount of primer extended by one nucleotide
(primer 1). The ratio of the primer band to the primer 1 band was obtained from the PhosphorImager data and is presented as nanomolar P. E is the amount
of enzyme (0.1 nM RT).
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AZTMP-terminated primers, presumably by stabilizing the posi-
tioning of AZTMP at the N site.
DISCUSSION
We investigated the effects of the M41L, L210W, and T215Y mu-
tations on the polymerase activity of HIV-1 RT and their effects on
the ability of mutant enzymes to excise AZTMP. Our data indicate
that subtle shifts in the ability of the mutant RTs to accomplish
these two related tasks govern which combinations of mutations
are selected in the virus in response to AZT therapy. There must be
a balance between the ability of RT mutations to increase the bind-
ing of ATP for the excision reaction and any potentially negative
effects that these mutations would have on the normal polymer-
ization activity of the RT. As we reported previously, the T215Y
mutation increases the ability of HIV-1 RT to excise AZTMP from
the 3= end of the primer using ATP as a pyrophosphate donor;
however, at the same time, the T215Y mutation decreases the abil-
ity of RT to use low to moderate concentrations of dNTPs to carry
out normal polymerization (17). At first glance, these results are
confusing, since both reactions use the same polymerase active
site. A possible resolution of this apparent paradox lies in the fact
that the two reactions use different substrates, which is essential if
the mutant enzymes are going to have an increase in their ability to
excise AZTMP relative to their ability to incorporate AZTTP:
primer-AZTMP ATP¡ primer-OH ATP-PP-AZTMP, and
primer-OH dNTP/AZTTP¡ primer-dNMP/AZTMP PPi.
We performed a biochemical analysis to dissect the effects of
the M41L, L210W, and T215Y mutations on the two reactions.
From the structure, it is clear that the primary role of the T215Y
mutation is to provide a binding site for the adenosine ring of
ATP. The improved ATP binding significantly increases the exci-
sion reaction (Fig. 1A); our excision assays confirm this result.
However, it is also clear from our polymerase assays that T215Y
has a deleterious effect on the normal polymerization reaction;
why this would happen is not clear from the reported structures.
We previously proposed that in order for the mutant RTs to be
more effective in viral replication, the M41L and L210W muta-
tions reduce the deleterious effects of T215Y on the polymerase
activity of RT without decreasing its ability to excise AZTMP from
the primer. The biochemical studies that we report here suggest
that these secondary mutations increase the ability of RTs carrying
the T215Y mutation to excise AZTMP. The initial excision reac-
tions were performed by using 3.0 mM ATP. This concentration
has served as the benchmark by many of the groups who have
performed AZTMP excision assays because it is considered to be
the physiological concentration of ATP in dividing cells (15, 18,
23, 25). However, this might not be the concentration that the RT
sees during polymerization in some infected cells. Several studies
suggested that the presence of the L210W mutation in RT causes a
decrease in AZT susceptibility (7, 11, 12, 21, 30). However, in our
experiments, when the ATP concentration was 3.0 mM, the triple
mutant containing L210W was not significantly better in the ex-
cision/extension assay than the M41L/T215Y mutant. We saw dif-
ferences in the excision/extension assay for the triple mutant com-
pared to the double mutant when the ATP concentration was
reduced (0.6 mM). This suggests that the levels of ATP that the RT
encounters in some infected cells may not be as high as expected
(3.0 m). An obvious possibility is that there is a significant
amount of HIV replication taking place in nondividing T cells or
in other cells where the ATP concentration is3 mM (15, 18, 23,
25). If so, the presence of the L210W mutation could allow more
efficient binding of ATP at lower concentrations. It is also clear
that the presence of the M41L mutation improves the polymeriza-
tion ability of an RT carrying the L210W mutation and that
L210W can improve the polymerization ability of an RT contain-
ing T215Y but, interestingly, only when M41L is also present (Fig.
5A and B). The mechanism by which the M41L and L210W mu-
tations accomplish this is unknown. Kinetic analysis of the differ-
ent RTs provides some insights into how the mutations affect the
process of polymerization (Table 1). A general scheme for an en-
zyme-catalyzed reaction can be defined as
E S ^
K1
K1
ES→
K2
EP→
K3
E P
In the presence of an excess of the nucleic acid substrate, which
was the case in our experiments, the enzyme (E) is RT, the variable
substrate (S) is the dNTP being tested, and the product (P) is the
dNMP joined to the primer. As described above,Km represents the
amount of substrate (dNTP) needed to reach one-half Vmax. It can
also be considered a ratio of all the rate constants involved in
enzyme-substrate (ES) formation: Km
 (k1 k2)/k1. Therefore,
mutations that decrease the ability of RT to bind the dNTP sub-
strates (k1 and k1) and/or how well the RT catalyzes the polym-
erization step (k2) will increase the Km, indicating that the muta-
tion (or mutations) has a deleterious effect on RT. For most of the
reactions that we ran, the T215Y mutant had an elevated Km com-
pared to those of the other RTs, indicating that this mutant RT has
a decreased ability to bind dNTPs and/or a decreased ability to
polymerize. For the most part, the M41L/T215Y and M41L/
L210W/T215Y mutants have lowerKm values than does the T215Y
mutant alone; they are closer to the WT in this regard. kcat can be
used to determine if the catalytic reaction is altered (binding of
dNTPs might still be affected, but this calculation allows exami-
nation of polymerization itself). In the reaction described above,
kcat is usually equivalent to k2, which is the rate constant of the
catalytic step. In the polymerization reaction, the T215Y mutant
has a kcat value significantly below that of WT RT, indicating that
this mutant has a problem with catalysis.
Although it is clear how the T215Y mutation helps RT bind
ATP to improve excision, modeling and structural analyses have
not offered any obvious insights into how T215Y impairs the poly-
merase activity of mutated RT. The T215Y mutation is 9.0 Å
from the polymerase active site. It is also 9 Å away from the
TABLE 2 Presence of various mutations in RTa
Mutation that must
be present
Other AZT resistance mutations
M41L L210W T215Y T215F
M41L 58.0 (60.8) 75.2 (75.7) 13.1 (11.8)
L210W 93.0 (92.7) 89.1 (88.5) 4.2 (3.7)
T215Y 84.5 (86.5) 62.3 (66.4)
L210W/T215Y 94.6 (94.7)
a The presence of the various mutations in RT was determined by using the Stanford
University HIV Drug Resistance Database (http://hivdb.stanford.edu/). The genotype
treatment section was used to identify sequences that were selected by NRTI therapy.
Samples where the treatment was unknown were excluded, since the presence of AZT
could not be confirmed. The queries specified which amino acid(s) should be present in
the sequences (left column). The percentages of other mutations present in these RT
sequences were obtained from the database. The database was first examined for all
subtypes and then just for subtype B (percentages in parentheses).
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-phosphate of a bound dNTP (Fig. 1A) and does not appear to be
in a position to interfere with dNTP binding. L210W enhances the
effects of the T215Y mutation in the excision reaction and reduces
the negative impact of T215Y on the polymerization reaction. Sev-
eral models have been proposed for the role(s) of M41L and
L210W in the excision reaction; however, none of them have sig-
nificant experimental support. In our assays, the addition of
L210W to the T215Y mutant reduced polymerization activity rel-
ative to that with T215Y alone, and compared to T215Y, the dou-
ble mutant had a similar level of excision activity. Although it is
relatively easy to envision an interaction between L210W and
T215Y which could affect the position of the side chain of T215Y
(2), which might enhance excision, it is much less clear how this
might affect (enhance) polymerization.
Similarly, it is not clear how the addition of the M41L muta-
tion, at a distance of 13 Å from T215Y site and 14 Å from the
polymerase active site, improves the ability of the T215Y mutant
to carry out either polymerization or AZTMP excision (Fig. 1A
and C). It is not known whether the addition of M41L would affect
the position of T215Y and, if it did, what the effect would be. In the
apo-AZT-R structure, the addition of M41L does not appear to
alter the position or orientation of Y215, nor does L41 seem to
alter the position of any amino acid, even the putative target F116
(Fig. 1C).
It is possible that the T215Y mutation indirectly distorts the
polymerase active site in a way that impairs the binding and in-
corporation of dNTPs in the polymerase reaction. However, be-
cause both the polymerization reaction and the excision reaction
directly involve the polymerase active site, any distortion that im-
pairs the polymerase activity is likely to also impair excision. Y215
is relatively far from the polymerase active site; the nucleobase of
ATP (the moiety with which amino acid Y at position 215 is
known to interact) is 9.0 Å away from the catalytic triad (D110,
D185, and D186) (Fig. 1A). This means that the T215Y mutation
should be able to have a much greater effect on ATP binding than
on the polymerase active site, which is why it causes the increased
excision that underlies AZT resistance. However, the T215Y mu-
tation, by itself, has a significant negative impact on polymerase
activity. It is possible that if the T215Y mutation has an indirect
effect on the polymerase active site, M41L serves to ameliorate any
distortions caused by T215Y and, perhaps, also enhances the bind-
ing and/or positioning of the AZTMP moiety on the end of the
primer at the N site. Both of these roles could also enhance exci-
sion. In this scenario, the L210W mutation could potentially affect
the positioning of T215Y through aromatic interactions of the
amino acid side chains; this could, perhaps, relieve distortions at
the active site caused by the T215Y mutation. Our data suggest
that M41L must be present for the L210W mutation to be effec-
tive. The structure of an unliganded HIV-1 RT containing the
D67N/K70R/T215F/K219Q mutation shows some changes in
the positions of the three aspartate amino acids that coordinate the
two Mg2 ions at the polymerase active site (31). However, this
structure was solved by using an unliganded form of RT that had
neither a bound nucleic acid nor an incoming dNTP. It is not clear
whether the distortions seen in this unliganded structure would
have any impact on dNTP binding. Structures of RTs carrying the
T215Y mutation, either alone or with M41L, did not show any
distortion at the polymerase active site (32). Again, no dNTPs or
nucleic acids were present in these structures. RT structures con-
taining the T215Y mutation, with a double-stranded DNA tem-
plate/primer and either with or without the product of the exci-
sion reaction (AZTppppA) bound at the active site, did not show
any major changes in the polymerase active site (Fig. 1A) (2). At
this point, a model in which the M41L and L210W mutations
correct a distortion of the polymerase active site caused by T215Y
is not strongly supported by the available structures.
We are considering a mechanism for how the L210W and
M41L mutations might exert their effects, which might not be
detected by crystallographic analysis. Previous studies of protease
inhibitor (PI) resistance mutations in HIV-1 PR suggested that
some PR mutations contribute to the flexibility of the hydropho-
bic core of the enzyme, a mechanism that has been called hydro-
phobic sliding (33, 34). In this mechanism, some of the resistance
mutations that reduce the susceptibility of PR to PIs allow some of
the hydrophobic core residues in PR to exchange interactions,
allowing the residues (and the enzyme) more conformational flex-
ibility, which in turn affects the processing of the cleavage sites in
the HIV-1 polyproteins and reduces the binding of PIs that pre-
vent these essential cleavages (33, 34).
Many of the primary drug resistance mutations found in
HIV-1 give a modest to robust level of resistance, but resistance
oftentimes comes at a cost to the replicative fitness of the virus.
Secondary mutations can increase the fitness of the virus, increase
the level of resistance, or both. For the secondary AZT resistance
mutations that we tested, it appears that they can do both, based
on our in vitro analysis of their effects on purified RT in assays that
measure various aspects of the polymerase activity of RT and its
ability to excise AZT and complete a short DNA product (using
the excision/extension assay, which is designed to measure the
susceptibility of RT and, by extension, the virus to inhibition by
AZTTP). Moreover, in excision/extension assays, some of the sec-
ondary mutations had a greater impact with relatively low levels of
ATP (0.6 mM) than at the concentration that is normally used for
assays of this type (3.0 mM). As discussed above, the actual con-
centration of ATP in the cells in which the virus normally repli-
cates in patients is not known; however, the fact that the secondary
mutations appear to have an impact on excision at the lower ATP
level suggests that, in at least some of the infected cells, the ATP
concentration in the environment in which RT normally operates
is probably 3.0 mM. This might be because an important frac-
tion of viral replication occurs in quiescent cells, because the ATP
in the cell may not have unfettered access to the RT that is present
in the reverse transcriptase complex, or both.
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